Compare APEI & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APEI | PRME |
|---|---|---|
| Founded | 1991 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 653.8M | 666.1M |
| IPO Year | 2007 | 2022 |
| Metric | APEI | PRME |
|---|---|---|
| Price | $43.50 | $3.53 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 5 |
| Target Price | ★ $42.43 | $6.42 |
| AVG Volume (30 Days) | 204.2K | ★ 3.3M |
| Earning Date | 03-05-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 133.01 | N/A |
| EPS | ★ 1.30 | N/A |
| Revenue | ★ $654,642,000.00 | $5,977,000.00 |
| Revenue This Year | $4.89 | $95.64 |
| Revenue Next Year | $6.76 | N/A |
| P/E Ratio | $32.03 | ★ N/A |
| Revenue Growth | 6.75 | ★ 647.13 |
| 52 Week Low | $18.77 | $1.11 |
| 52 Week High | $44.88 | $6.94 |
| Indicator | APEI | PRME |
|---|---|---|
| Relative Strength Index (RSI) | 64.03 | 40.98 |
| Support Level | $40.80 | $4.08 |
| Resistance Level | $44.88 | $4.21 |
| Average True Range (ATR) | 1.79 | 0.37 |
| MACD | -0.06 | -0.07 |
| Stochastic Oscillator | 76.50 | 8.05 |
American Public Education Inc provides online and campus based postsecondary education including various undergraduate and graduate degree programs. The fields of study include business administration, health science, technology, criminal justice, education, liberal arts, national security, military studies, intelligence, and homeland security. There are three reporting segments: the American Public University segment which is the key revenue generator; the Rasmussen University Segment and the Hondros College of Nursing segment. The revenue is generated from net course registrations and enrollment, tuition rate, net tuition, and other fees.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.